Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christopher Schumann

Cardiovascular Disease Greensboro, NC Medical Doctor

NPI 1871869065 CMS profile 1351334

3200 Northline Ave Ste 250, Greensboro, NC 27408

Open in the dashboard

General payments

$15,710

219 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Schumann of Greensboro, NC is reported in the CMS Open Payments database as having received $15,710 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,275 15
2024 General $988 52
2023 General $7,126 60
2022 General $974 68
2021 General $347 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Schumann
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Christopher Schumann were reported at $6,275. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Christopher Schumann Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $347 $335 $101–$1,037 $132
2022 $974 $395 $121–$1,211 $149
2023 $7,126 $443 $136–$1,283 $160
2024 $988 $450 $136–$1,323 $164
2025 $6,275 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. HeartFlow, Inc. $12,199 8 payments
  2. Amgen Inc. $628 39 payments
  3. Novartis Pharmaceuticals Corporation $507 32 payments
  4. AstraZeneca Pharmaceuticals LP $286 17 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $276 16 payments
  6. Janssen Pharmaceuticals, Inc $251 17 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $231 14 payments
  8. Pfizer Inc. $197 11 payments
  9. Sanofi-Aventis U.S. LLC $127 6 payments
  10. Lexicon Pharmaceuticals, Inc. $124 6 payments
  11. Other $884 53 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $12,000 2 payments
  2. Food and Beverage $3,710 217 payments
Products named General payments · program years 2021–2025
  1. FFRct $12,199 8 payments
  2. Repatha $539 34 payments
  3. XARELTO $251 17 payments
  4. LEQVIO $249 14 payments
  5. Kerendia $231 14 payments
  6. JARDIANCE $193 12 payments
  7. ENTRESTO $145 10 payments
  8. VYNDAQEL $140 7 payments
  9. VERQUVO $116 8 payments
  10. MULTAQ $115 5 payments
  11. Other $1,603 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

3,135

Median for Cardiology: 2,533

Drug cost

$563,178

Median for Cardiology: $485,213

Branded share of claims

23.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 316 $265,319
Repatha Sureclick Evolocumab Brand 126 $119,899
Jardiance Empagliflozin Brand 61 $58,359
Entresto Sacubitril/Valsartan Brand 36 $36,950
Xarelto Rivaroxaban Brand 20 $26,106
Farxiga Dapagliflozin Propanediol Brand 28 $25,387
Atorvastatin Calcium Generic 333 $4,566
Rosuvastatin Calcium Generic 378 $4,009
Metoprolol Succinate Generic 286 $3,722
Ezetimibe Generic 192 $2,993

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$55,776

Medicare's payments for the services billed

Medicare patients

766

Average age 76

Services billed

1,490

378 women, 388 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
Arthritis 48%
Atrial fibrillation 47%
Heart failure 45%
Diabetes 37%
Chronic kidney disease 36%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $182
$182 126 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $89
$89 28 —
XARELTO
  • Janssen Pharmaceuticals, Inc $85
$85 20 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $83
$83 61 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record